U.S.S.N.: 09/020,393
Filed: February 9, 1998
AMENDMENT

In the Claims

1. (amended) A compound ~~that specifically~~ inhibits the formation of the ~~hu~~ human C5b-9 complex selected from the group consisting of ~~molecules structurally mimicking CD59 amino acid residues 42 to 58 when they are in a spatial orientation which inhibits formation of the hu C5b-9 complex, wherein the compound is not hu CD59~~ a peptidomimetic having the structure and function of human CD59 amino acid residues 42-58 of SEQ ID NO:3 selected from the group consisting of a peptide, a nucleic ~~acids~~ acid, and a small molecule and an anti-ID anti-CD59 amino acid residues 42-58 antibody, the peptidomimetic and an anti-CD59 antibody binding specifically to human C9 at amino acid residues 26-51 of SEQ ID NO:14.

2. (amended) The compound of claim 1, selected from the group consisting of ~~proteins,~~ peptides, nucleic acids, and small molecules which bind specifically to amino acids ~~359 to 384~~ 26-51 of ~~hu~~ human C9 in SEQ ID NO:14.

E,

3. (amended) The compound of claim 2, wherein the ~~protein~~ compound is an antibody.

4. (amended) The compound of claim 2, wherein the ~~protein~~ compound is a chimeric peptide which includes the amino acids 42 to 58 of the human sequence of CD59 in SEQ ID NO:3.

5. (amended) The compound of claim 2, wherein the ~~peptide~~ compound is a covalently cyclized peptide comprising ~~hu~~ human CD59 amino acid residues 42 to 58 in SEQ ID NO:3.

6. (amended) The compound of claim 2, wherein the ~~composition~~ compound is a peptide of less than ~~forty amino acids~~ residues including amino acid residues 42 to 58 of ~~hu~~ human CD59 in SEQ ID NO:3

7. (amended) ~~The compound of claim 1, further~~ A composition comprising a compound that specifically inhibits the formation of the human C5b-9 complex selected from the group consisting of a peptidomimetic having the structure and function of human CD59 amino acid residues 42-58 of SEQ ID NO:3 selected from the group consisting of a peptide, a nucleic ~~acids~~ acid, and a small molecule and an anti-ID anti-CD59 amino acid residues 42-58 antibody, the peptidomimetic and an anti-CD59 antibody binding specifically to amino acid residues 26 to 51 of human C9 in SEQ ID NO:14, and a pharmaceutically acceptable carrier for administration to patients in need thereof.

E.1

8. The compound of claim 1 wherein the compound is a peptidomimetic compound comprising the side chains of ~~hu~~ human CD59 amino acid residues His^{44}, Asn^{48}, Asp^{49}, Thr^{51}, Thr^{52}, Arg^{55}, and Glu^{58} of SEQ ID NO:3 in an equivalent spatial orientation and alignment to that presented on the surface of ~~hu~~ human CD59.

9. The compound of claim 8 wherein the spatial orientation and alignment of the side chains of His^{44}, Asn^{48}, Asp^{49}, Thr^{51}, Thr^{52}, Arg^{55}, and Glu^{58} of SEQ ID NO:3 in the compound are equivalent to the spatial orientation and alignment deduced by NMR structure determination.

10. (three times amended) A method for inhibiting human C5b-9 complex assembly comprising administering ~~to a patient in need thereof~~ an effective amount of a composition comprising a compound binding specifically to amino acid residues 26 to 51

of human C9 in SEQ ID NO:14 selected from the group consisting of ~~a peptidomimetic~~ having the structure and function of human CD59 amino acid residues 42-58 in SEQ ID NO:3 selected from the group consisting of ~~proteins, peptides~~ a peptide, a nucleic ~~acids~~ acid, and a small molecule ~~molecules having the structure and function of human CD59 amino acid residues 42-58~~, and an anti-ID anti-CD59 amino acid residues 42-58 antibody, the peptidomimetic and anti-CD59 antibody ~~binding specifically to amino acid residues 359-384 of human C9~~.

11. (three times amended) The method of claim 10, wherein the compound is a peptidomimetic that is a small molecule which binds specifically to amino acids ~~359 to 384~~ 26 to 51 of human C9 SEQ ID NO:14.

E, 1

12. (twice amended) The method of claim 10, wherein the ~~protein~~ compound is an antibody.

13. (three times amended) The method of claim 10, wherein the ~~protein~~ compound is a chimeric peptide which includes the amino acids 42 to 58 of the human sequence of CD59 in SEQ ID NO:3.

14. (three times amended) The method of claim 10, wherein the ~~peptide~~ compound is a covalently cyclized peptide comprising human CD59 amino acid residues 42 to 58 in SEQ ID NO:3.

15. (three times amended) The method of claim 10, wherein the ~~peptidomimetic~~ compound is a peptide of less than forty amino acids residues including amino acid residues 42 to 58 of human CD59 in SEQ ID NO:3.

16. (original) The method of claim 10, wherein the composition further comprises a pharmaceutically acceptable carrier for administration to patients in need thereof.

17. (once amended) The method of claim 10, wherein the composition is administered to a patient ~~is~~ in need of suppression of complement-mediated inflammation.

E1

18. (twice amended) The method of claim 10 wherein the compound is a peptidomimetic ~~comprises~~ comprising the side chains of human CD59 amino acid residues His^{44}, Asn^{48}, Asp^{49}, Thr^{51}, Thr^{52}, Arg^{55}, and Glu^{58} of SEQ ID NO:3 in the spatial orientation and alignment of ~~hu~~ human CD59.

19. (once amended) The method of claim 18 wherein the spatial orientation and alignment of the side chains of His^{44}, Asn^{48}, Asp^{49}, Thr^{51}, Thr^{52}, Arg^{55}, and Glu^{58} of SEQ ID NO:3 in the compound are deduced by NMR structure determination.

Please cancel claims 20-35.